Clinical Trial: Comparative Effectiveness of Cephalexin Plus Trimethoprim-Sulfamethoxazole Versus Cephalexin Alone for Treatment of Uncomplicated Cellulitis: A Randomized Controlled Trial

Clicks: 235
ID: 118265
2013
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
To date, no trial has assessed the effectiveness of antibiotics that target community-associated methicillin-resistant Staphylococcus aureus in the treatment of
Reference Key
j.2013clinicalclinical Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Pallin, Daniel J.;Binder, William D.;Allen, Matthew B.;Lederman, Molly;Parmar, Siddharth;Filbin, Michael R.;Hooper, David C.;Camargo, Carlos A.;
Journal clinical infectious diseases
Year 2013
DOI
DOI not found
URL
http://dx.doi.org/10.1093/cid/cit122
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome research support non-u.s. gov't adult adolescent aged middle aged young adult Child Comparative Study preschool Randomized Controlled Trial Double-Blind Method Multicenter Study anti-bacterial agents / adverse effects anti-bacterial agents / administration & dosage* drug therapy combination trimethoprim staphylococcal skin infections / microbiology cellulitis / microbiology staphylococcal skin infections / drug therapy daniel j pallin carlos a camargo methicillin-resistant staphylococcus aureus / isolation & purification sulfamethoxazole drug combination / adverse effects cellulitis / drug therapy* pmid:23457080 doi:10.1093/cid/cit122 william d binder cephalexin / administration & dosage* cephalexin / adverse effects sulfamethoxazole drug combination / administration & dosage*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.